[1]何丽,林永红,李笑晓,等.防己诺林碱联用紫杉醇对耐药卵巢癌SKOV3/ADM细胞作用机制的初步研究[J].中国计划生育和妇产科,2017,(6):59-62.
 HE Li,LIN Yong-hong,LI Xiao-xiao,et al.Effect of fangchinoline combined with paclitaxel on drug resistant ovarian cancer SKOV3 / ADM cells: a preliminary study[J].Chinese Journal of Family Planning & Gynecotokology,2017,(6):59-62.
点击复制

防己诺林碱联用紫杉醇对耐药卵巢癌SKOV3/ADM细胞作用机制的初步研究
分享到:

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2017年6期
页码:
59-62
栏目:
论著与临床
出版日期:
2017-06-25

文章信息/Info

Title:
Effect of fangchinoline combined with paclitaxel on drug resistant ovarian cancer SKOV3 / ADM cells: a preliminary study
作者:
何丽1林永红1李笑晓2张芸榕2杨俊毅2*
1. 610091四川成都,成都市妇女儿童中心医院妇产科;2. 610041四川成都,四川大学华西药学院临床药学研究中心
Author(s):
HE Li1LIN Yong-hong1LI Xiao-xiao2ZHANG Yun-rong2 YANG Jun-yi2*
1. Department of Gynaecology and Obstetrics,Maternal and Children’s Hospital of Chengdu, Chengdu Sichuan 610091, P.R.China;2.West China School of Pharmacy, Sichuan University, Chengdu Sichuan 610041, P.R.China
关键词:
防己诺林碱紫杉醇卵巢癌多药耐药MTT试验
Keywords:
fangchinolinepaclitaxelovarian cancer multidrug-resistanceMTT tests
分类号:
R 73053
摘要:
目的评价防己诺林碱调控紫杉醇对耐药卵巢癌SKOV 3/ADM细胞多药耐药的作用。方法采用MTT法和细胞摄取研究防己诺林碱调控紫杉醇对SKOV 3/ADM细胞多药耐药的作用。结果细胞生长抑制试验表明,紫杉醇对SKOV 3/ADM细胞耐药明显。05、1和 5 μg·mL-1浓度的防己诺林碱分别与紫杉醇联用后,紫杉醇对细胞的半数抑制浓度(IC50)降为(0542±0117)、(0924±0153)和(1931±0375)μg·mL-1,耐药逆转倍数 If 分别为161、94和45倍,与单用紫
Abstract:
Objective To evaluate multidrug resistance of SKOV3/ADM cell for paclitaxel regulated by fangchinoline. MethodsMTT tests and cell uptaking were adopted to research the activity of fangchinoline in regulating the multidrug resistance effect of paclitaxel t

参考文献/References:

[1]WANG Biao, LI Shuo, MENG Xin, et al Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells [J] Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, 36 (8) : 6433-6443. [2]ASSANHOU A G, LI Wenyuan, ZHANG Lei, et al. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment [J]. Biomaterials, 2015, 73 (11): 284-295. [3]CHEN Yanzuo, ZHANG Wei, HUANG Yukun, et al. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor [J]. International Journal of Pharmaceutics, 2015, 488 (1/2) : 44-58. [4]TAUB M E, PODILA L, ELY D, et al. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity [J]. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005, 33 (11) : 1679-1687. [5]ZHANG Yilin, SRIRAMAN S K, KENNY H A, et al. Reversal of chemoresistance in ovarian cancer by Co-Delivery of a P-Glycoprotein inhibitor and paclitaxel in a liposomal platform [J]. Molecular Cancer Therapeutics, 2016, 15 (10) : 2282-2293. [6]何丽,杨俊毅,胡丽娜.防己诺林碱调控紫杉醇在MDR1-MDCKⅡ细胞模型中的跨膜转运研究 [J].中国中药杂志,2010,35(11):1478-1481. [7]WANG Jinfeng, LIU Wenming, TU Qin, et al. Folate-decorated hybrid polymeric nanoparticles for chemically and physically combined paclitaxel loading and targeted delivery [J]. Biomacro-molecules, 2011, 12 (1) : 228-234. [8]BERNABEU E, GONZALEZ L, LEGASPI M J, et al. Paclitaxel-Loaded TPGS-b-PCL nanoparticles: in vitro cytotoxicity and cellular uptake in MCF-7 and MDA-MB-231 cells versus mPEG-b-PCL nanoparticles and abraxane? [J]. Journal of Nanoscience and Nanotechnology, 2016, 16 (1) : 160-170. [9]WANG Feihu, ZHANG Dianrui, ZHANG Qiang, et al. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance [J]. Biomaterials, 2011, 32 (35) : 9444-9456. [10]LUO Xue, PENG Jian-ming, SU Lan-di, et al. Fangchinoline inhibits the proliferation of SPC-A-1 lung cancer cells by blocking cell cycle progression [J]. Experimental and Therapeutic Medicine, 2016, 11 (2) : 613-618.

相似文献/References:

[1]张雪梅.紫杉醇联合洛铂化疗方案对晚期初治卵巢癌术后 患者早期临床疗效及毒副反应发生率的分析[J].中国计划生育和妇产科,2018,(2):72.
 ZHANG Xue-mei.Early clinical efficacy and side effects of paclitaxel combined with lobaplatin regimen on postoperative patients with advanced ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(6):72.

备注/Memo

备注/Memo:
四川省卫生厅科学研究项目(项目编号:110069)
更新日期/Last Update: 2017-06-25